# Codex Review: medical_monitoring_formal_reviewer_provenance_package_20260802

Date: 2026-08-02 19:46 CST
Execution: Codex direct; no native sub-agent, Hermes model, conference, or
runner was dispatched because the user required autonomous direct execution.
Evidence: `records/active_slices/medical_monitoring_formal_reviewer_provenance_package_20260802/B6_FORMAL_REVIEWER_PROVENANCE_PACKAGE.json`

## Verdict

**Pass for a read-only reviewer/provenance handoff; B6 remains pending.** The
package is current, deterministic and source-hash bound. It does not approve a
candidate, prove historical aggregate application, resolve the MY009 token, or
grant runtime authority.

## Boundary Check

- No delegated agent was dispatched. Writes stayed within the declared
  task-owned context/prompt/review/metrics and `records/active_slices/`
  evidence surfaces; the runner-reserved report path was not written.
- No B6/C14/release/runtime/SQLite/API/provider/browser/service/real-project
  write occurred. 8911/5174 remain stopped and protected product/medical-writing
  surfaces were not touched.

## Codex Verification

- Package replay passed: 11/11 source manifest hashes, 5/5 candidate IDs and
  fingerprints, 5/5 engineering defer records, 5/5 reviewer field sets left
  `not_provided`, and 9/9 authority flags false.
- Package hash recomputation passed with
  `fa9f37fcc3c6314e7ddf743336a0b0ceb2e341ff5eb00fb415508212ac02710c`.
- Focused regression passed: **37 passed** (release gate, aggregate/CAS replay,
  and B6 activation gate).
- Browser/PPT/PDF/live-authority checks are not applicable to this read-only
  evidence package and were not run.

## Delegated-Agent Output Review

No delegated-agent output exists to review. The package links each candidate to
the current B6 fingerprint/outcome, source-version evidence, shared metadata
chain and CAS replay case. The formal reviewer fields are explicit
`not_provided`; no missing fact is inferred. Scope stayed within evidence
packaging and did not alter gate state.

## Residual Risk

Residual risks remain: formal medical/engineering reviewer outcomes are absent;
MY009 legacy source-token revalidation is unproven; B4 CAS `expected_version`
evidence is absent; C14 and commercial release remain fail-closed. The next
action is a separately hash-bound reviewer outcome submission, then only if
blockers close an approved-input dry-run.
